Wall Street analyst estimates for bioAffinity Technologies, Inc. (BIAF): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 0 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 1 |
| Avg rating (1-5) | 0.00 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-18 | $-31.50 | ||
| 2026-08-07 | $-9.60 | $-31.50 | +69.5% |
| 2026-05-08 | $-0.81 | $-2.40 | +66.2% |
| 2026-03-13 | $-1.11 | $-2.70 | +58.9% |
| 2025-11-14 | $-4.74 | $-2.70 | -75.6% |
| 2025-08-14 | $-5.10 | $-3.00 | -70.0% |
| 2025-05-15 | $-4.80 | $-4.80 | +0.0% |
| 2025-03-31 | $-6.31 | $-4.20 | -50.2% |
Valuation Ratios
| Price / Book | 0.49 |
| EV / EBITDA | -0.19 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | $4803 | $2.5M | $9.4M | $6.2M |
| Cost of Revenue | $40278 | $22242 | $4817 | $467 | $1.7M | $6.0M | $4.7M |
| Gross Profit | -$40278 | -$22242 | -$4817 | $4336 | $791615 | $3.4M | $1.4M |
| Research & Development | $1.9M | $1.6M | $1.1M | $1.5M | $1.7M | $1.8M | $2.1M |
| Selling, General & Admin | $1.2M | $972101 | $1.1M | $2.5M | $6.8M | $9.9M | $9.9M |
| Operating Expenses | $3.1M | $2.6M | $2.2M | $4.0M | $8.8M | $12.3M | $12.0M |
| Operating Income | -$3.1M | -$2.6M | -$2.2M | -$4.0M | -$8.0M | -$9.0M | -$10.6M |
| EBITDA | -$3.0M | -$6.9M | -$5.3M | -$5.6M | -$7.6M | -$8.3M | -$14.3M |
| Interest Expense | $214834 | $382171 | $1.0M | $2.5M | $37125 | $92475 | $44372 |
| Pre-tax Income | -$3.3M | -$7.3M | -$6.3M | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| Income Tax | $3200 | $2750 | $1950 | $2459 | $20993 | $11650 | $44042 |
| Net Income | -$3.3M | -$7.3M | -$6.3M | -$8.2M | -$7.9M | -$9.0M | -$14.9M |
| EPS | $-202.50 | $-445.50 | $-1062.90 | $-814.50 | $-409.50 | $-337.50 | $-129.90 |
| EPS (Diluted) | $-202.50 | $-445.50 | $-1043.55 | $-814.50 | $-409.50 | $-337.50 | $-129.90 |
| Shares Outstanding (Diluted) | $16396 | $16396 | $6062 | $9998 | $19440 | $26956 | $114739 |
Price
| Price | $5.35 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ARTL · CARM · GTBP · LIPO · MNDR · PBM · PTIX
Explore sector: Healthcare · Medical - Diagnostics & Research
More sections of BIAF: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks